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Abstract 
Objectives: To study first and second/third trimester levels of soluble fms-like tyrosine kinase 1 
(sFlt1), placental growth factor (PlGF) and soluble endoglin (sEng) in (FINNPEC case-control 
cohort. The participants were further divided into subgroups based on parity and onset of the 
disease. Recommended cut-off values in aid of pre-eclampsia prediction and diagnosis were also 
tested. 
Methods: First trimester serum samples were available from 221 women who later developed pre- 
eclampsia and 239 women who did not develop pre-eclampsia. Second/third trimester serum 
samples were available from 175 pre-eclamptic and 55 non pre-eclamptic women. sFlt-1 and PlGF 
were measured electro-chemiluminescence immunoassays and sEng by ELISA. 
Results: In all timepoints PlGF, endoglin and the sFlt-1/PlGF ratio were increased in the PE group 
compared to the non-PE group. The serum concentrations of sFlt-1 were increased only at 
second/third trimester in PE women. Higher concentrations of s-Flt1, endoglin and higher sFlt/PlGF 
ratio were found at the third trimester in primiparous women compared to multiparous women. 
Primiparous PE women also had lower concentrations of PlGF at the third trimester. The proportion 
of women exceeding all cut-offs of the sFlt-1/PlGF ratio (≥33, ≥38, ≥85 and ≥110) was greater in 
the PE group, but there were also pre-eclamptic women who met rule-out cut-off or did not meet 
rule-in cut-off. 
Conclusions: Primiparous pregnancies have more anti-angiogenic profile during second/third 
trimester compared with multiparous pregnancies. Our findings also suggest that certain maternal 
characteristics, e.g. BMI, smoking and pre-existing diseases, should be taken into account when 
different sFlt-1/PlGF ratio cut-offs are utilized. 
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1.Introduction 
 
Pre-eclampsia (PE) is a complex pregnancy disorder, defined by new-onset hypertension and 
proteinuria after 20 weeks of gestation, or new onset preeclampsia-associated signs in the absence 
of proteinuria [1]. Currently there is no treatment for PE other than delivery, which often leads to 
premature birth due to indicated delivery. As one of the major conditions causing maternal and 
fetal morbidity and mortality, it is a global challenge for maternal and fetal health care providers 
[2]. Due to incomplete understanding of the pathogenesis and subtypes of this heterogeneous 
disorder a development of predictive tools, prevention and treatments poses a challenge. 
 
 
An imbalance of maternal proangiogenic placental growth factor (PlGF) and antiangiogenic soluble 
fms-like tyrosine kinase 1 (sFlt-1) has been implicated in the prediction and outcomes of PE [2-4]. 
The sFlt-1/PlGF ratio is elevated in patients with PE and it is better predictor of the early-onset 
disease (delivery < 34 weeks of gestation) than the late-onset disease [3,5]. It has been suggested 
that syncytiotrophoblast stress contributes to the angiogenic imbalance especially in the early-onset 
disease with poor placentation [6] but angiogenic markers are released also from maternal sources 
[7]. With accumulating evidence for the importance of angiogenic markers as a diagnostic and 
prognostic marker, different cut-offs have also been defined to allow an assessment of PE [Fig. 1, 
2,4,8,9]. 
 
 
In this nested case-control study we investigated first and second/third trimester levels of sFlt-1, 
PlGF and their ratio in addition to soluble endoglin in the Finnish Genetics of Pre-eclampsia 
Consortium (FINNPEC) case-control cohort. The participants were further divided into subgroups 
based on onset of the disease and parity. We also tested recently recommended rule-out cut-off 
value 33 (20 weeks to delivery), rule-in cut-offs 85 (ad 33weeks 6days) and 110 (34 weeks to 
delivery) for the Elecsys immunoassay sFlt-1/PlGF ratio [10]. Furthermore, we tested a cut-off for 
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the sFlt-1/PlGF ratio that was presented recently in the PROGNOSIS study [2]. Zeisler et al. [2] 
derived a single cut-off value independent of the weeks of gestation; values below 38 were 
considered negative and were used to rule-out PE within 1 week after assessment of the ratio. 
Moreover, data on pregnancy associated placental protein A (PAPP-A) and beta human chorionic 
gonadotrophin (ß-hCG) were measured in the first trimester biochemical screening for fetal 
chromosomal abnormalities. 
 
 
Fig. 1. The sFlt-1/PlGF ratio cut-offs recommended in aid of pre-eclampsia prediction and diagnosis. 
 
 
 
 
2.Methods 
 
2.1. Design 
 
FINNPEC is a cross-sectional case-control multicentre study with an established nationwide clinical 
and DNA database on PE women and women without PE, including their partners and infants in 
order to identify genetic risk factors for PE. Details of the study design, methods and procedures 
have been described elsewhere [11]. With this study we aimed to investigate whether maternal 
serum concentrations of sFlt-1, PlGF, endoglin and sFlt-1/PlGF ratio available from a subset 
associate with PE and clinical subtypes. 
 
 
2.2. Study subjects 
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Originally 1450 patients with PE and 1065 control women without PE were recruited at the 5 
Finnish university hospitals. In this study, we focused on a prospective arm and on a subset of those 
women from whom first and second/third trimester serum samples were available. All PE women 
were already diagnosed at recruitment and second/third trimester serum samples were also drawn at 
this timepoint. All participants provided written informed consent, and the FINNPEC study 
protocol was approved by the coordinating Ethics Committee of the Hospital District of Helsinki 
and Uusimaa. 
 
 
2.2.1 Inclusion criteria 
 
Nulliparous or multiparous women with a singleton pregnancy were eligible for the study. PE was 
defined as hypertension and proteinuria occurring after 20 weeks of gestation. Hypertension was 
defined as systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg and 
proteinuria as the urinary excretion of ≥0.3 g protein in a 24-hour specimen, or 0.3g/l, or two ≥1+ 
readings on dipstick in a random urine determination with no evidence of the urinary tract infection. 
Each diagnosis was ascertained based on hospital records and confirmed independently by a 
research nurse and a study physician. 
 
 
2.2.2. Exclusion criteria 
 
Exclusion criteria were multiple pregnancy, maternal age less than 18 years and inability to 
provide an informed consent based on information in Finnish or Swedish. 
 
 
2.3. Background, obstetric and perinatal data 
 
Extensive information on pregnancy complications, pregnancy outcome, proteinuria, blood 
pressure, laboratory measurements, delivery and baby was obtained from the hospital records and 
maternity cards. Information on PE in previous pregnancies was verified from the hospital records. 
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PE was defined as early-onset when delivery occurred before 34+0 weeks of gestation and late- 
onset when at 34+0 weeks of gestation or later. Birth weights below −2.0 SD units were classified 
as small-for-gestational age (SGA) according to Finnish standards [12]. 
 
 
Hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome was diagnosed when 
at least 2 of the following criteria were met: lactate dehydrogenase (LD) ≥ 235 U/l, alanine 
aminotransferase (ALAT) ≥ 70 U/l, aspartate aminotransferase (ASAT) ≥ 70 U/l, and thrombocytes 
≤ 100 E9/l. 
 
 
 
2.4. Serum samples and angiogenic markers 
 
First and second/third trimester serum samples were collected from a subcohort from the Hospital 
District of Helsinki and Uusimaa. First trimester serum samples were obtained via first trimester 
biochemical screening for fetal chromosome abnormalities (range 9-15 weeks of gestation), and 
during the second and third trimesters (range 20-42 weeks of gestation) serum samples were 
collected at hospitals. The results on angiogenic markers measured from samples obtained during 
the second and third trimesters were further divided into early/late based on the timing of the blood 
sampling (early: 20-33+6 weeks of gestation and late sample ≥34 weeks of gestation). 
 
 
Maternal serum sFlt-1 and PlGF concentrations were measured using sFlt-1 and PlGF electro- 
chemiluminescence immunoassays (ECLIA; Roche Diagnostics GmbH, Mannheim, Germany) on 
cobas e 601 analyzer (Hitachi High Technology Co, Tokyo, Japan). Serum concentration of 
endoglin (CD105) was measured using human Quantikine Endoglin ELISA kit (R&D Systems, 
UK) according to manufacturer’s instructions. 
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Pregnancy associated placental protein A (PAPP-A) and beta human chorionic gonadotrophin (ß- 
hCG) were analyzed by time-resolved fluoroimmunoassay according to manufacturer's instructions 
(PerkinElmer, Wallac, Turku, Finland). 
 
 
2.5. Statistical analysis 
 
Statistical tests were performed with IBM SPSS Statistics version 24. The normality of variable 
distributions was verified with the Kolmogorov–Smirnov test. Logarithmic transformation was used 
when appropriate. Each biomarker was ln-transformed to correct for right-skewness, and estimated 
means were back-transformed as geometric means and 95% confidence intervals for purposes of 
presentation. For the continuous variables, comparisons between groups were analysed with general 
linear model univariate ANOVA at baseline and with linear mixed models during the pregnancy. 
Selected co-variables [parity, maternal age, smoking status, body mass index (BMI), gestational 
weeks at sampling] were included in the models as covariates. Normality was assessed by plotting 
the residuals. 
For the categorical variables, the comparisons were performed with the Fisher’s exact test. With 
skewed distributions, comparisons between continuous variables were performed by the Mann 
Whitney U-test. 
 
 
3. Results 
 
As published earlier for the whole FINNPEC population [11], in this subcohort the PE women had 
higher BMI and more frequently certain preexisting medical conditions (e.g. chronic hypertension, 
pregestational diabetes) and gestational diabetes than controls (Table 1). The proportion of 
primiparous women was also higher in the PE group (Table 1). At first trimester screening, both 
PAPP-A and ß-hCG concentrations were lower in the PE group compared to the control group. 
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Serum concentrations of angiogenic markers are presented in Table 2. In all timepoints PlGF, 
endoglin and the sFlt-1/PlGF ratio were increased in the PE group compared to the control group. 
The serum concentrations of sFlt-1 was increased only at second/third trimester in PE women 
compared to non-PE women. The proportion of women exceeding all cut-offs of the sFlt-1/PlGF 
ratio (≥33, ≥38, ≥85 and ≥110) was greater in the PE group (Table 2). However, there were also 
pre-eclamptic women who met NICE rule-out cut-off 33 at second/third trimester (n=10) or did not 
meet rule-in cut-off 85 (ad 33weeks 6days) (n=8) and 110 (n=4) (34 weeks to delivery). Ten PE 
women who did not exceed rule-out cut-off 33 had higher prepregnancy BMI, smoked more before 
pregnancy, suffered more from renal disease, had more often a history of PE and the relative birth 
weight of the newborn was higher (Table 3a). Moreover, eight PE women did not exceed cut-off 
85. The basic characteristics of these women are presented in Table 3b. Also these PE women had 
a trend for higher prepregnancy BMI and the relative birth weight of the newborn was higher. There 
were four control women who exceeded the cut-off 110 and the comparison of these women with or 
without exceeding cut-off 110 is presented in Table 3c. These four women suffered more from 
placental insufficiency and had a trend for having SGA babies. Three of these control women 
exceeded the rule-in cut-off already before 34 weeks of gestation. 
 
 
There where altogether 49 PE women of whom serum samples were available one week before the 
delivery. Of those women, only one woman did not exceed cut-off 38. In addition, there were four 
control women who exceeded cut-off 38 within a week of the delivery. Two of these women had 
gestational hypertension and SGA baby. 
 
 
There were altogether 18 women with the HELLP syndrome (5.8%) of whom first and/or third 
serum samples were available. These women fulfilled also PE criteria, 7 of them had early- and 11 
late-onset disease. PE women with HELLP syndrome had higher concentration of second/third 
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trimester sFlt-1 and sFlt-1/PlGF ratio when compared with PE women without HELLP syndrome 
(data not shown). 
 
 
Onset of PE 
 
Table 4 shows the comparison of angiogenic markers between women with early- or late-onset PE 
and controls. At the first trimester those women with early-onset disease had decreased 
concentrations of PlGF and increased concentrations of endoglin compared to women with late- 
onset disease. At second/third trimester women in the early-onset disease had highest 
concentrations of sFlt-1, endoglin and elevated sFlt-1/PlGF ratio. There was no difference in the 
proportions of women with early- or late-onset disease exceeding the cut-off values of 33 or 38 
(Table 4). Both cut-offs 85 and 110 covered greater proportion of PE women with early-onset 
disease compared to women with late-onset disease. However, when analyses were adjusted for 
parity, BMI, mother’s age, gestational weeks at sampling and smoking status during pregnancy, the 
difference was not significant. 
 
 
Parity 
 
Primiparous PE women had lower second/third trimester PlGF concentration and higher 
concentrations of sFlt-1 and endoglin compared to multiparous PE women (Table 5). Primiparous 
PE women had also had higher sFlt-1/PlGF ratio at the second/third trimester. Within the control 
group, similar differences between primi- and multiparous women were only observed for sFlt-1 
and sFlt-1/PlGF ratio at the second/third trimester. 
There were greater proportion of primiparous PE women exceeding cut-offs 33 and 38 at the third 
trimester compared to multiparous PE women. In addition, there were more primiparous women 
exceeding cut-offs 85 and 110 after 34 weeks of gestation than multiparous PE women. There were 
no similar differences within control group. 
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4. Discussion 
 
In this study we found that primiparous pregnancies had more anti-angiogenic profile during 
second/third trimester compared with multiparous pregnancies. Our findings also suggest  that 
certain maternal characteristics should be taken into account when different sFlt-1/PlGF ratio cut- 
offs are utilized in the clinic. For instance, PE women who met NICE sFlt-1/PlGF ratio rule-out cut- 
off 33 at second/third trimester had higher prepregnancy BMI, smoked more before pregnancy, and 
had more often renal disease and history of PE. 
In general, our results support the increasing evidence that the pathogenesis of PE involves an 
imbalance between angiogenic and anti-angiogenic markers. Serum concentrations of sFlt-1, 
endoglin and sFlt-1/PlGF ratio levels are usually found to be higher and PlGF levels lower in the PE 
pregnancies, but absolute levels vary markedly between studies [2, 12, 13]. However, these factors 
have also limitations as PE biomarkers, especially for prediction and diagnosis of PE at term [14]. 
 
 
Maternal ß-hCG and PAPP-A have also gained acceptance as potential predictors of PE at the first 
trimester [15]. In the current study, we were able to confirm all these previously observed 
differences in angiogenic markers except in higher sFlt-1 concentration at first trimester. 
Onset of PE 
 
In line with the previous literature [16] we found increased serum endoglin at second/third trimester 
to be associated with early-onset disease. However, to our knowledge, this is the first study to show 
increased serum endoglin concentration in the early-onset PE already at first trimester. At the 
second/third trimester sFlt-1 concentration and s-Flt1/PlGF ratio were also higher in PE women 
with early-onset disease compared to the late-onset group. Furthermore, serum PlGF concentration 
was lower at the first trimester in women who later developed early-onset PE compared to women 
who had late-onset PE and compared to controls. PlGF is thought to exert a direct pro-angiogenic 
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activity, and it has been demonstrated that the levels of PlGF are decreased early in pregnancies 
later complicated by PE [17]. Khalil et al. [18] have also shown that maternal serum PlGF is a 
useful marker for PE from the first trimester onward, while the level of sFlt-1 is likely to have a 
predictive value from the second trimester onward. Furthermore, it has been demonstrated that 
serum PlGF is lower in early-onset PE than in late-onset PE, with no difference in serum sFlt-1 
[19]. Our finding that the second/third trimester sFlt-1/PlGF ratio was higher in early-onset PE is in 
agreement with previous findings [3,20,21]. There were no differences in the number women in the 
early- and the late onset groups exceeding cut-offs of 33 or 38. Accordingly, in this study sFlt-1 
concentration and sFlt-1/PlGF ratio were not associated with early-onset PE at first trimester which 
is in contrast to some of the previous studies [22,23]. Whereas there were greater proportions of 
women in the early- onset group exceeding cut-offs 85 and 110. These finding highlight the theory 
that early- and late-onset PE have different pathophysiologic pathways. In late-onset PE there is a 
broader spectrum of involved mechanisms possibly due to underlying maternal conditions and 
endothelial injury whereas early-onset PE is more closely related to placental dysfunction and 
angiogenic imbalance [24-26]. 
 
 
Early-onset PE is also associated with higher perinatal and maternal morbidity and mortality than 
late-onset disease, mainly due to gestational age at delivery [27]. However, very recently 
Christensen [28] showed that particularly gestational age at PE onset including the early-onset/late- 
onset distinction was associated with subclinical atherosclerosis 12 years after delivery. However, 
more studies on the predictive role of angiogenic markers in augmented risk for future 
cardiovascular disease are warranted. 
The use of angiogenic markers in the first-trimester prediction of early-onset PE would be clinically 
relevant since low-dose aspirin started before 16 weeks’ gestation may be effective in the 
prevention of the disease or postponing the onset of the disease [29]. 
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Parity 
 
Nulliparity is a well-known risk factor for PE with a reported incidence of up to 2–3 times higher 
than in multiparous pregnancies [30]. The mechanisms explaining this epidemiological observation 
have been postulated to involve e.g. immune maladaptation and greater insulin resistance [31]. 
There are relatively few studies on the association between parity and circulating angiogenic 
markers. Higher sFlt1 levels have been reported in the first and second trimester of nulliparous 
women [32, 33]. Furthermore, Bdolah et al. [34] have shown that nulliparous women have higher 
circulating sFlt1 concentration and sFlt1/PlGF ratio than multiparous women during the late third 
trimester. Consistent with Bdolah et al. [34], we also demonstrated higher concentration of s-Flt1 
and higher sFlt/PlGF ratio at the third trimester in primiparous PE and control women compared to 
multiparous women. We also observed higher levels of circulating endoglin in primiparous PE 
women at the third trimester. Furthermore, primiparous PE women had lower concentrations of 
PlGF at the third trimester compared to multiparous women. It is notable that these differences were 
observed in analyses adjusted for most potential confounding factors (maternal BMI, age, smoking 
status and gestational weeks in sampling). There were also greater proportion of primiparous PE 
women exceeding all the cut-offs at third trimester compared to multiparous PE women, but there 
were no differences between primi- and multiparous PE women in cut-offs 85 or 110 if sample was 
obtained before 34 weeks of gestation. All these findings add further support to previous 
speculations that altered angiogenic profile may be a potential molecular mechanism that explains 
the link between PE and nulliparity. More studies are needed to understand the causal mechanism 
behind the phenomenon. 
 
 
Cut-offs 
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Although there are no formal guidelines regarding the use of the sFlt-1/PlGF ratio, consensus 
statements have been developed by international experts on the clinical use of the Elecsys 
immunoassay sFlt-1/PlGF ratio. Previously it has been shown that not all women complicated with 
PE have altered pro- and anti-angiogenic profile [35]. Accordingly, we observed PE women (n=10) 
who met NICE rule-out cut-off 33 at second/third trimester. They had higher BMI, smoked more 
before pregnancy and suffered more from renal disease. Moreover, eight pre-eclamptic women who 
did not exceed cut-off 85 had a trend for higher BMI. Although the current guidelines are not based 
on women with clinically confirmed PE, as in our study design, we suggest that certain maternal 
characteristics, particularly BMI, should be taken account when different sFlt-1/PlGF ratio cut-offs 
are utilized in the clinic. We have recently demonstrated within the same cohort that smoking 
before and during pregnancy may complicate the use of angiogenic markers as a prognostic and 
diagnostic marker [36]. Furthermore, there are a few studies indicating that an imbalance of 
angiogenic markers is mild in obese pregnant women [32,37]. 
 
 
We conclude that the imbalance of pro- and anti-angiogenic markers is unlikely to be a primary 
pathophysiologic feature of PE in those women and there indeed may be angiogenic and non- 
angiogenic forms of PE as suggested earlier [26, 35, 38]. The findings that there were controls e.g. 
with placental insufficiency exceeding the cut-offs implicate that angiogenic imbalance is not 
exclusively limited to PE pregnancies. Obviously we cannot exclude the possibility that these 
women had developed PE later if the pregnancy had continued. 
 
 
Zeisler et al. [2] have derived a cut-off value of 38 to serve as an aid in the short-term prediction of 
PE. They proposed this single cut-off rules out PE within one week. In our study, only one PE 
woman did not exceed cut-off 38 before the delivery. However, it was notable that there were four 
control women who exceeded cut-off 38 a week before the delivery. 
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5. Strengths and limitations 
 
Our study has several strengths. A major strength of this study is its prospective cohort design with 
detailed clinical outcome information allowing to define accurately the phenotypes. In future, the 
combination of the angiogenic markers with clinical characteristics may substantially improve PE 
prediction. Detailed phenotyping enabled us to involve various adjustments for maternal 
characteristics and highlighted the importance of selection of clinical covariates when analysing the 
role of angiogenic markers in the etiology PE. 
 
 
Our study has certain limitations. The sample size was limited especially when subdividing into 
categories. It should also be noticed that PE and control groups were not matched for gestation at 
sampling although this was taken account in the statistical analyses. Furthermore, the gestation at 
sampling for the first trimester blood samples varied from 9 to 15 weeks and this relatively wide 
time period might have affected e.g. the concentrations observed for sFlt-1. Moreover, there was 
only limited number of samples available from the second trimester. However, samples from first 
and second/third trimester within this study make possible to analyse changes over time. 
 
 
 
 
6. Conclusions 
 
In conclusion, we were able to confirm previously observed differences in angiogenic markers 
except in higher sFlt-1 concentration at first trimester. In future, special attention should be aimed 
to disentangle the role of angiogenic markers within the different maternal characteristics. 
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Table 1. Maternal and perinatal characteristics of pre-eclamptic and control groups in a subset of the FINNPEC women. 
 
Maternal or Perinatal Characteristics Pre-eclampsia 
(n=221) 
Control 
(n=239) 
p* p** 
Age at delivery (y) 30.3 ± 5.3 30.5 ± 4.8 0.495*** 0.661b 
Nulliparous, n (%) 166 (75.1%) 137 (57.3%) <0.001  
BMI, kg/m2 (self-reported, pre-pregnancy) 25.5 ± 5.1 23.9 ± 3.9 0.005*** <0.001c 
PAPP-A (mU/l)j 1455 ± 1193 (214) 1952 ± 1209 (236) <0.001*** <0.001a 
Beta hCG (ug/l)j 45.3 ± 30.1 (214) 54.4 ± 40.3 (236) 0.038 0.005a 
Highest systolic blood pressure (mm Hg)h 165 ± 17 127 ± 14 <0.001*** <0.001 
Highest diastolic blood pressure (mm Hg) 110 ± 9 85 ± 10 <0.001*** <0.001 
Proteinuria (max.) (g/24 h) 3.7 ± 3.2 (211) - -  
Smoking before pregnancy 58 (26.9%) (216) 57 (23,9%) (238) 0.003  
Smoking during pregnancy 24 (11.0%) (218) 20 (8.4%) (238) 0.005  
Chronic hypertensionf 33 (14.9%) 8 (3.3.%) <0.001  
Gestational hypertensiong - 21 (8.8%) -  
Gestational diabetes mellitus 28 (12.7%) 13 (5.4.%) 0.007  
Pregestational diabetes mellitus 
Type 1 diabetes 
Type 2 diabetes 
12 (5.4%) 
11 (5.0%) 
1 (0.5%) 
1 (0.4%) 
1 (0.4%) 
- 
0.001  
Mode of delivery 
Vaginal 
Caesarean section 
133 (60.2%)88 (39.8%)  
197 (82.7%) 
41 (17.3%) (238) 
<0.001  
Gestational weeks at delivery 36.8 ± 3.3 39.3 ± 2.6 <0.001  
Birth weight, g 2792 ± 851 3476 ± 717 <0.001*** 0.001e 
Relative birth weight (SD) 
Fetal sex, female/male (%) 
-0.9 ± 1.3 
52.9%/47.1% 
-0.2 ± 1.2 
55.6%/44.4% 
<0.001 
0.042 
0.003e 
SGA 35 (15.8%) 18 (7.5%) 0.005  
*unadjusted; **adjusted; ***non-parametric tests used 
()number of available information/samples unless from all. 
Data are presented as mean ± S.D or percentages 
aadjusted for gestational weeks at sampling 
badjusted for parity 
cadjusted for parity, mother’s age at birth 
dadjusted for parity, mother’s age at birth, prepregnancy BMI 
21  
eadjusted for parity, mother’s age at birth, gestation weeks, prepregnancy BMI, chronic hypertension, gestational diabetes, pregestational diabetes mellitus 
fsystolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg detected before 20 weeks of gestation. 
gblood pressure ≥140/90, no proteinuria 
hwhen highest diastolic value recorded 
ibased on weight and height before pregnancy, self-reported at first antenatal visit. 
jPAPP-A and beta hCG samples were obtained at 9-15 weeks of gestation. 
BMI= body mass index, PAPP-A= placental protein A, ß-hCG= beta human chorionic gonadotrophin,SGA small-for-gestational age 
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Table 2. Concentrations of angiogenic markers in pre-eclamptic and control women of FINNPEC, geometric mean (95% CI). 
 
 Pre-eclampsia 
I trimester n=221 
II/III  trimester n=175 
Early sample (20-33+6), n=48 
Late sample (>34), n=127 
Control 
I trimester n=239 
II/III  trimester n=55 
Early sample (20-33+6), n=9 
Late sample (≥34), n=46 
punadj. p*adj. 
sFlt-1 (pg/ml) 
I trimester 
II-III trimester 
 
1303.9 (1232.3-1379.5) 
(n=220) 
10356.8 (9403.2-11406.1) 
(n=175) 
 
1388.1 (1322.0-1457.4) 
4278.1 (3621.7-5053.8) 
 
0.097 
<0.001 
 
0.349 
<0.001 
PlGF (pg/ml) 
I trimester 
II-III trimester 
 
31.3 (29.5-33.2) (n=220) 
81.0 (73.5-89.4) 
 
41.8 (39.8-43.9) 
164.6 (130.7-207.3) 
 
<0.001 
<0.001 
 
<0.001 
<0.001 
Endoglin (ng/ml) 
I trimester 
II-III trimester 
 
5.9 (5.7-6.1) (n=220) 
41.7 (37.7-46.2) 
 
5.6 (5.4-5.8) 
16.6 (14.0-19.6) 
 
0.035 
<0.001 
 
0.005 
<0.001 
sFlt-1/PlGF 
I trimester 
II-III trimester 
 
 
42 (39-45) (n=220) 
188 ± 180b 
 
33 (31-35) 
45 ± 47b 
 
<0.001 
<0.001*** 
 
<0.001 
na 
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are presented as geometric mean (95%CI) or percentages 
 
*adjusted for parity, prepregnancy BMI, mother’s age at birth, gestational weeks at sampling, smoking status during pregnancy 
***Mann-Whitney U-test 
a logistic regression adjusted for parity, prepregnancy BMI, mother’s age at birth, gestational weeks at sampling, smoking status during pregnancy 
barithmetic mean ± SD 
cχ2 –test 
na=test not applicable 
()nu 
mbe 
r of 
avai 
labl 
e 
info 
rma 
tion 
/sa 
mpl 
es 
unle 
ss 
fro 
m 
all 
Dat 
a 
sFlt-1/PlGF ratio, ≥33 
II-III trimester 
 
165 (94.3%) 
 
22 (40.0%) 
 
<0.001c 
 
<0.001a 
sFlt-1/PlGF ratio, ≥38 
II-III trimester 
 
160 (91.4%) 
 
20 (36.4%) 
 
<0.001c 
 
<0.001a 
sFlt-1/PlGF ratio, ≥85 rule-in 
II-III trimester 
Early sample (20-33+6) 
 
123 (70.3%) 
40 (83.3%) 
 
10 (18.2%) 
3 (37.5%) 
 
<0.001c 
0.012c 
 
<0.001a 
0.004a 
sFlt-1/PlGF ratio, ≥110 rule-in 
II-III trimester 
Late sample (≥34) 
 
110 (62.9%) 
71 (55.9%) 
 
7 (12.7%) 
4 (8.7%) 
 
<0.001c 
<0.001c 
 
<0.001a 
<0.001a 
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Table 3a. Characteristics of pre-eclamptic women according to the sFlt-1/PlGF ratio cut-off 33. 
 II-III trim sFlt-1/PlGF 
≤33 in pre-eclamptic 
(n=10) 
II-III trim sFlt-1/PlGF 
>33 in pre-eclamptic 
(n=165) 
pa 
Age 29.8 ± 5.3 31.2 ± 5.9 0.425 
Prepregnancy BMI 
Parity 
29.2 ± 5.4 
2.1  ± 2.7 
25.3 ± 5.6 
0.4  ± 1.4 
0.020 
0.001 
Previous PE 5 (50.0%) 23 (13.9%) 0.003 
Smoking before pregnancy 7 (70.0%) 37 (22.4%) 0.001 
Smoking during pregnancy 1 (10.0%) 12 (7.3%) 0.754 
Placental insufficiency 0 (0.0%) 25 (15.2%) 0.184 
Renal disease 4 (40.0%) 7 (4.2%) <0.001 
Chronic hypertension 3 (30.0%) 33 (20.0%) 0.447 
Birth weight 3445.0 ± 775.7 2546.6 ± 877.4 <0.001 
Relative birth weight, SD 
SGA 
0.6 ± 0.9 
0 (0.0%) 
-1.2 ± 1.3 
42 (25.5%) 
<0.001 
0.067 
Gestational weeks of delivery 37.1 ± 3.1 36.0 ± 3.4 <0.001 
 
Table 3b. Characteristics of pre-eclamptic women according to the sFlt-1/PlGF ratio cut-off 85. 
 
 II-III trim (20-33+6 
gwks) 
sFlt-1/PlGF ≤85 in 
pre-eclamptic (n=8) 
II-III trim (20-33+6 
gwks) 
sFlt-1/PlGF  >85 in pre- 
eclamptic (n=40) 
pa 
Age 30.0 ± 5.7 31.4 ± 6.1 0.562 
Prepregnancy BMI 
Parity 
28.9 ± 5.0 
0.6 ± 1.4 
25.8 ± 5.7 
0.5 ± 1.9 
0.057 
0.862 
Previous PE 1 (12.5%) 4 (10.0%) 1.000 
Smoking before pregnancy 3 (37.5%) 10 (25.0%) 0.664 
Smoking during pregnancy 2 (25.0%) 4 (10.0%) 0.258 
Placental insufficiency 2 (25.0%) 18 (45.0%) 0.440 
Renal disease 1 (12.5%) 2 (5.0%) 0.429 
Chronic hypertension 2 (25.0%) 14 (35.0%) 0.701 
Birth weight 1976.3 ± 723.1 1469.4 ± 544.6 0.028 
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Relative birth weight, SD 
SGA 
-1.0 ± 0.9 
1 (12.5%) 
-2.1 ± 1.0 
21 (52.5%) 
0.004 
0.055 
Gestational weeks of delivery 32.4 ± 4.0 31.4 ± 2.7 0.134 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3c. Characteristics of controls according to the sFlt-1/PlGF ratio cut-off 110. 
 II-III trim (>34 gwks) 
sFlt-1/PlGF > 110 in 
controls (n=4) 
II-III trim (>34 gwks) 
sFlt-1/PlGF ≤ 110 in 
controls (n=42) 
pa 
Age 33.0 ± 9.4 31.1 ± 4.8 0.395 
Prepregnancy BMI 
Parity 
26.7 ± 3.4 
0.5 ± 1.0 
24.2 ± 3.5 
0.5 ± 0.7 
0.160 
0.948 
Previous PE 0 (0%) 0 (0%) - 
Smoking before pregnancy 2 (50.0%) 14 (33.3%) 0.602 
Smoking during pregnancy 0 (0%) 3 (7.1%) 0.580 
Placental insufficiency 2 (50.0%) 2 (4.8%) 0.033 
Renal disease 0 1 (2.4%) 0.755 
Chronic hypertension 1 (25.0%) 1 (2.4%) 0.168 
Birth weight 
Relative birth weight, SD 
2849.0 ± 1167.2 
-1.3 ± 1.9 
3596.8 ± 561.9 
0.1 ± 1.1 
0.315 
0.245 
SGA 2 (50.0%) 3 (7.1%) 0.053 
Gestational weeks of delivery 38.3 ± 3.8 39.6 ± 1.7 0.585 
anon-parametric test 
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Table 4. Concentrations of angiogenic markers in pre-eclamptic (early and late onset) and control women, geometric mean (95% CI). 
dj. 
vs. 
trol 
Maternal or 
Perinatal 
Characteristics 
Pre-eclampsia p*adj. Con 
Early onset Late onset early vs. late 
(delivery ≤ 34 weeks 
of gestation) 
trol p*adj. p*a 
early vs. late 
control
 co
n 
 
sFlt-1(pg/ml) 
I trimester 
II-III trimester 
 
1274 (1076 – 1495) 
(33) 
13227 (10509 – 16548) 
(37) 
 
1313 (1233-1392) (188) 0.585 
9897 (8736-10783) 0.006 
(138) 
 
1388 (1322-1457) 0.23 
4278 (3621-5053) <0.0 
(n=55) 
 
4 0.464 
01 <0.001 
PlGF (pg/ml) 
I trimester 
II-III trimester 
 
 
25.5 (22.2-29.5) (33) 
47.9 (36.7-62.9) (37) 
 
32.5 (30.5-34.6) (187) 0.002 
92.8 (85.3-102.0) (138) 0.097 
 
41.8 (39.8-43.9) <0.0 
164.6 (130.7-207.3) 0.02 
(n=55) 
 
01 <0.001 
0 <0.001 
Endoglin (ng/ml) 
I trimester 
II-III trimester 
 
6.6 (6.0-7.3) (33) 
64.7 (48.8-86.3) (37) 
 
5.8 (5.6-6.0) (187) 0.009 5.6 (5.4-5.8) <0.0 
37.0 (33.6-40.9) (138) <0.001 16.6 (14.0-19.6) <0.0 
(n=55) 
 
01 0.046 
01 <0.001 
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sFlt-1/PlGF 
I trimester 
II-III trimester 
 
 
49 (40-61) (33) 
375 ± 271 (37) b 
 
40 (38-43) (187) 
137 ± 100 (138)b 
 
0.031 
(test not available) 
 
33 (31-35) 
45 ± 47 (n=55)b 
 
<0.001 
na 
 
<0.001 
na 
sFlt-1/PlGF ratio, 
≥33 
II-III trimester 
 
 
36 (97.3%) 
 
 
129 (93.5%) 
 
 
0.744a 
 
 
22 (40.0%) 
 
 
0.092a 
 
 
<0.001a 
sFlt-1/PlGF ratio, 
≥38 
II-III trimester 
 
 
36 (97.3%) 
 
 
124 (89.9%) 
 
 
0.371a 
 
 
20 (36.4%) 
 
 
0.010a 
 
 
<0.001a 
sFlt-1/PlGF ratio, 
≥85 
II-III trimester 
Early sample 
 
 
33 (89.2%) 
33 (89.2%) 
 
 
90 (65.2%) 
7 (63.6%) 
 
 
0.069a 
0.196a 
 
 
10 (18.2%) 
3 (37.5%) 
 
 
0.001a 
0.996a 
 
 
<0.001a 
0.064a 
sFlt-1/PlGF ratio, 
≥110 
II-III trimester 
Late sample 
 
 
33 (89.2%) 
- 
 
 
77 (55.8%) 
71 (55.9%) 
 
 
0.182a 
- 
 
 
7 (12.7%) 
4 (8.7%) 
 
 
<0.001 
- 
 
 
<0.001a 
<0.001a 
**adjusted for parity, prepregnancy BMI, mother’s age at birth, gestational weeks at sampling, smoking status during pregnancy 
alogistic regression adjusted for parity, prepregnancy BMI, mother’s age at birth, gestational weeks at sampling, smoking status during pregnancy 
barithmetic mean ± SD; cχ2 –test; dMann-Whitney U-test 
na=test not applicable 
 
 
 
Table 5. Concentrations of angiogenic markers in pre-eclamptic and control women according to the parity status, geometric mean (95% CI). 
p* 
for PE 
multipara vs. 
control 
multipara 
Maternal or 
Perinatal 
Characteristics 
Pre-eclampsia p* Control 
Primipara Multipara (primi vs. Primipara Multipara 
multiparas) 
p* 
(primi vs. 
multiparas) 
p* 
for PE 
primipara 
vs. control 
primipara 
  
sFlt-1 (pg/ml) 
I trimester 
 
II-III trimester 
 
1318.0 (1235.3- 
1406.1) (166) 
11610.9 (10527.0- 
12807.7) (128) 
 
1262.1 (1121.3- 0.304 
1420.6) (55) 
7585.6 (6065.1- 0.001 
9488.2) (47) 
  
1392.1 (1299.2- 1382.6 (1291.9- 
1491.7) (137) 1479.7) (102) 
5023.6 (4044.5- 3229.9 (2572.9- 
6239.2) (35) 4044.5) (20) 
 
0.484 
 
0.005 
 
0.429 
 
<0.001 
  
0.338 
 
<0.001 
PlGF (pg/ml)  
30.7 (28.6-32.8) 
 
33.5 (29.9-37.5) 0.691 
  
41.1 (38.4-43.9) 42.8 (39.7-46.1) 
 
0.852 
 
<0.001 
  
0.001 
 
28  
 
I trimester 
 
 
 
II-III trimester 
(166) 
75.4 (67.2-84.7) 
(128) 
(54) 
98.5 (82.5-117.6) 
(47) 
 
0.015 
(137) 
147.8 (118.2-185.0) 
(35) 
(102) 
198.6 (117.7-335.2) 
(20) 
 
0.097 
 
<0.001 
 
0.033 
Endoglin (ng/ml) 
I trimester 
II-III trimester 
 
6.0 (5.7-6.2) (166) 
47.6 (42.8-53.1) 
(128) 
 
5.8 (5.3-6.3) (54) 
29.1 (23.4-36.1) 
(47) 
 
0.619 
<0.001 
 
5.7 (5.4-5.9) (137) 
18.5 (14.8-23.2) 
(35) 
 
5.5 (5.2-5.8) (102) 
13.6 (10.8-23.2) 
(20) 
 
0.098 
0.063 
 
0.047 
<0.001 
 
0.066 
<0.001 
sFlt-1/PlGF 
I trimester 
II-III trimester 
 
43 (40-44) (166) 
206 ± 184b (128) 
 
38 (33-44) (54) 
138 ± 160b (47) 
 
0.291 
<0.001** 
 
34 (31-37) (137) 
51 ± 47 b (35) 
 
32 (30-35) (102) 
36 ± 47 b (20) 
 
0.445 
0.022** 
 
<0.001 
<0.001 
 
0.042 
<0.001 
sFlt-1/PlGF 
ratio ≥33 
II-III trimester 
 
 
126 (98.4%) 
 
 
39 (83.0%) 
 
 
0.001a 
 
 
16 (45.7%) 
 
 
6 (30.0%) 
 
 
0.179a 
 
 
<0.001a 
 
 
0.004a 
sFlt-1/PlGF 
ratio ≥38 
II-III trimester 
 
 
126 (98.4%) 
 
 
34 (72.3%) 
 
 
<0.001a 
 
 
14 (40.0%) 
 
 
6 (30.0%) 
 
 
0.295a 
 
 
<0.001a 
 
 
0.048a 
sFlt-1/PlGF ratio, 
≥85 
II-III trimester 
Early sample 
 
 
100 (78.1%) 
32 (84.2%) 
 
 
23 (48.9%) 
8 (80.0%) 
 
 
0.001a 
0.377a 
 
 
7 (20.0%) 
2 (28.6%) 
 
 
3 (15.0%) 
1 (100%) 
 
 
0.602a 
0.375c 
 
 
<0.001a 
0.004a 
 
 
0.115a 
1.000c 
sFlt-1/PlGF ratio, 
≥110 
II-III trimester 
Late sample 
 
 
92 (71.9%) 
61 (67.8%) 
 
 
18 (38.3%) 
10 (27.0%) 
 
 
<0.001a 
<0.001a 
 
 
5 (14.3%) 
3 (11.1%) 
 
 
2 (10.0%) 
1 (5.3%) 
 
 
0.337a 
0.448c 
 
 
<0.001a 
<0.001a 
 
 
0.183a 
0.077c 
*adjusted for prepregnancy BMI, mother’s age at birth, gestational weeks at sampling and smoking status during pregnancy 
**unadjusted 
alogistic regression adjusted for prepregnancy BMI, mother’s age at birth, gestational weeks at sampling and smoking status during pregnancy 
barithmetic mean ± SD 
cχ2 –test 
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